{
    "Trade/Device Name(s)": [
        "Access CK-MB"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K234005",
    "Predicate Device Reference 510(k) Number(s)": [
        "K030012"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JHX"
    ],
    "Summary Letter Date": "December 18, 2023",
    "Summary Letter Received Date": "December 19, 2023",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1215"
    ],
    "Regulation Name(s)": [
        "Creatine Phosphokinase/Creatine Kinase Or Isoenzymes Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "CK-MB"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "Lithium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "DxI 9000 Access Immunoassay Analyzer",
        "Access Immunoassay System"
    ],
    "Method(s)/Technology(ies)": [
        "Paramagnetic particle chemiluminescent immunoassay",
        "Enzyme immunoassay (EIA)",
        "Two-site immunoenzymatic sandwich assay"
    ],
    "Methodologies": [
        "Chemiluminescent immunoassay",
        "Sandwich immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Beckman Coulter Access CK-MB assay, a chemiluminescent immunoassay for quantitative CK-MB determination using the Access Immunoassay Systems.",
    "Indications for Use Summary": "Quantitative determination of CK-MB in human serum and plasma using Access Immunoassay Systems to aid in diagnosis and treatment of myocardial infarction and progressive, Duchenne-type muscular dystrophy.",
    "fda_folder": "Clinical Chemistry"
}